For research use only. Not for therapeutic Use.
Zabofloxacin HCl（Cat No.:I010133）is a potent broad-spectrum fluoroquinolone antibiotic used primarily for the treatment of bacterial infections. It targets bacterial DNA gyrase and topoisomerase IV, inhibiting DNA replication and transcription, leading to cell death. Zabofloxacin HCl exhibits strong antibacterial activity against both Gram-positive and Gram-negative pathogens, including resistant strains. Its high potency and extended half-life make it effective in treating infections, including respiratory tract and urinary tract infections. Due to its selective action on bacterial enzymes, Zabofloxacin HCl has a favorable safety profile with minimal impact on host cells.
| Catalog Number | I010133 |
| CAS Number | 623574-00-5 (HCl) |
| Synonyms | DW-224; DW 224; DW224; DW-224a; PB-101; Zabofloxacin;(E)-1-cyclopropyl-6-fluoro-7-(8-(methoxyimino)-2,6-diazaspiro[3.4]octan-6-yl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid hydrochloride |
| Molecular Formula | C19H21ClFN5O4 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 1-cyclopropyl-6-fluoro-7-[(8E)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-1,8-naphthyridine-3-carboxylic acid;hydrochloride |
| InChI | InChI=1S/C19H20FN5O4.ClH/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17;/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28);1H/b23-14-; |
| InChIKey | IFPBSRFVNPCZMK-BJMORVNCSA-N |
| SMILES | CO/N=C\1/CN(CC12CNC2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5CC5)C(=O)O)F.Cl |
| Reference | </br> 1: Kim T, Park SJ, Chong YP, Park KH, Lee YM, Hong HL, Kim HS, Kim ES, Lee S, Choi DR, Kim SH, Jeong JY, Lee SO, Choi SH, Woo JH, Kim YS. Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. Diagn Microbiol Infect Dis. 2016 Jul 22. pii: S0732-8893(16)30227-9. doi: 10.1016/j.diagmicrobio.2016.07.019. [Epub ahead of print] PubMed PMID: 27498611.</br> 2:Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May 23;15(1):34. doi: 10.1186/s12941-016-0150-4. Review. PubMed PMID: 27215369; PubMed Central PMCID: PMC4878067.</br> 3:Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, Lee JH, Park MJ, Yoo KH, Oh YM. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial. Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2265-75. doi: 10.2147/COPD.S90948. eCollection 2015. PubMed PMID: 26543359; PubMed Central PMCID: PMC4622522.</br> 4: Van Bambeke F. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones. Ann Med. 2014 Nov;46(7):512-29. doi: 10.3109/07853890.2014.935470. Epub 2014 Jul 24. Review. PubMed PMID: 25058176. |
